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ABBREVIATIONS 
BrdU  5-bromo-2’-deoxyuridine 
C1orf10  chromosome 1 open reading frame 10 
GAPDH glyceraldehydes 3-phosphate dehydrogenase 
IPTG  isopropyl-1-thio-β-galactoside 
LOH  loss of heterozygosity 
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
OSCC  oral squamous cell carcinoma 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
PI  propidium iodide 
PVDF  polyvinylidine difluoride 
RT-PCR  reverse transcriptase-polymerase chain reaction 
SDS  sodium dodecyl sulfate 
TBS  Tris buffered saline 
Tris  Tris(hydroxymethyl)aminomethane 
TUNEL  terminal deoxynuleotidyl transferase mediated dUTP nick end labeling 
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GENERAL INTRODUCTION 
Calcium ions play an important role as a second messenger in a variety of 
signaling pathways. The modification in the intracellular calcium level alters 
physiological cellular functions such as muscle contraction, secretion, adhesion, synaptic 
transmission, cell cycle progression and cell differentiation. Calcium-binding proteins are 
then a family of unique importance in normal and aberrant cell biology. The EF-hand is a 
structure common to several calcium-binding proteins consisting of two perpendicular 10 
to 12 residue alpha helices with a 12-residue loop region in between, forming a single 
calcium-binding site (helix-loop-helix). The interaction of calcium ion with residues in 
the loop region causes structural changes leading to the exposure of hydrophobic patches, 
thought to be important for the interaction with specific proteins. S100 is a multigenic 
family of non-ubiquitous Ca2+-modulated proteins characterized with two sets of 
different EF-hands. S100 proteins are expressed in a cell and tissue-specific manner, and 
most of their genes are located in a gene cluster on human chromosome 1q21. Recently, 
many S100 proteins have been demonstrated to be involved in several human 
pathologies.  
C1orf10 is a recently identified gene that encodes a protein characterized with 
the presence of an EF-hand calcium-binding motif similar to S100 proteins. C1orf10 gene 
is located at chromosome 1q21 and like S100 family genes is composed of three exons 
and two introns. C1orf10 was identified as a gene expressed specifically in esophageal 
epithelium and a candidate of tumor suppressor gene in esophageal squamous cell 
carcinoma. In previous study, I detected the down-regulation of C1orf10 in human oral 
squamous cell carcinoma (OSCC) tissues compared with its expression in normal oral 
tissue by an in-house cDNA microarray. To study the function of C1orf10 in oral cancer I 
analyzed the effects of its overexpression in 3 OSCC-derived cell lines by transfection in 
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an Ecdysone-based expression system.[Chapter I] 
To further study the structure of S100 proteins, I cloned, expressed and purified 
human S100A13. S100A13 is one of the last members identified from the S100 protein 
family. This protein has interesting characteristics that distinguish it from other members 
of S100 family, such as the ubiquitous expression in various tissues, and the lack of 
conformational changes after calcium binding. Human S100A13 was expressed in E.coli 
and after several purifications methods the pure recombinant S100A13 was obtained for 
analysis of the three-dimentional structure.[Chapter II] 
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CHAPTER I 
 
 
C1orf10 GENE IS FREQUENTLY DOWN-REGULATED AND INHIBITS CELL 
PROLIFERATION IN ORAL SQUAMOUS CELL CARCINOMA 
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SUMMARY 
C1orf10 is a recently identified gene that encodes a protein with an EF-hand 
calcium-binding motif similar to S100 family proteins. Previous studies identified 
C1orf10 as a candidate of tumor suppressor gene in esophageal squamous cell carcinoma. 
In this study, to determine whether the loss of C1orf10 gene function could contribute to 
the development of oral squamous cell carcinoma (OSCC), we have evaluated the 
expression status of this gene by reverse transcriptase-polymerase chain reaction 
(RT-PCR) analysis and quantitative real-time PCR analysis. A high frequency of decrease 
in C1orf10 gene was detected not only in OSCC-derived cell lines but also in tumor 
tissues. Next, to define biological function of this gene in oral carcinogenesis, we 
transfected Clorf10 with an Ecdysone-inducible system in OSCC cell lines and analyzed 
the effects of its overexpression. Induction of C1orf10 expression resulted in a significant 
decline in the rate of cell proliferation, and in an arrest in the G1 phase of the cell cycle, 
with a down-regulation of Cyclin D1 expression. However, we could not detect 
significant difference in the percentage of apoptotic cells. Thus, our results suggest that 
the down-regulation of C1orf10 gene plays a role in oral carcinogenesis, and that its 
expression may negatively regulate OSCC cell proliferation by arresting the cell cycle 
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INTRODUCTION 
C1orf10 gene is a recently identified gene that encodes a protein characterized 
with the presence of an EF-hand calcium-binding motif similar to S100 proteins, a 
conserved repeated sequence with similarity with bacterial ice nucleation protein, and 
one transmembrane domain (1). C1orf10 was originally identified by differential display 
polymerase chain reaction (PCR) as one of the down-regulated genes in esophageal 
carcinoma (2). Its expression was highly detected in esophageal mucosa and dramatically 
reduced or absent in esophageal cancer cell lines and primary esophageal tissues (1). The 
expression of the C1orf10 gene was first proposed to be esophageal-specific, because its 
expression was undetectable in another 15 human adult tissues, i.e., the stomach, small 
intestine, colon, uterus, placenta, bladder, adipose, heart, brain, kidney, liver, lung, 
pancreas, spleen, and skeletal muscle (2). More recently, C1orf10 expression also was 
detected in human cervical squamous epithelium, murine skin, and normal oral mucosa (3, 
4). Therefore, the expression of C1orf10 is now believed to be squamous cell-specific. 
Oral cancer accounts for 2.6% of all cancers worldwide (5), and oral squamous 
cell carcinoma (OSCC) is the most frequently occurring malignancy in the oral cavity. 
Many structural aberrations in chromosomes and/or genes (6, 7), and epigenetic 
alterations, such as methylation (8-10), have been reported to play important roles in 
OSCC carcinogenesis. However, the molecular mechanisms and genetic changes 
associated with OSCC development remain to be identified. In our laboratory, an 
in-house cDNA microarray constructed from cDNA libraries of normal oral mucosa and 
OSCC allowed us to perform an accurate gene expression analysis of oral cancer (3). 
cDNA microarray analysis revealed down-regulated expression of several genes in 
OSCC, compared with normal oral mucosa. Of them, the C1orf10 gene was 
down-regulated by 0.08-fold in OSCC compared with that in normal oral mucosa (3). 
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In the current study, to confirm C1orf10 down-regulation in OSCC, I analyzed 
the expression level of this gene in 40 OSCC cases and examined the genetic mechanisms 
of its regulation. To define role of this gene in OSCC pathogenesis, I stably transfected 
C1orf10 in the OSCC-derived cell line SAS. The exogenous expression of C1orf10 
caused a decrease in cell proliferation and in the percentage of S-phase cells. The same 
result was found with other 2 transiently transfected OSCC-derived cells, HSC-3 and 
HSC-4. The results of this study therefore provide evidences that the down-regulation of 
C1orf10 is involved in OSCC proliferation.   
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MATERIALS AND METHODS 
Tissue samples 
 A total of 40 primary tumor tissue samples and corresponding surrounding 
normal tissues were obtained from 40 Japanese patients with OSCC at the time of surgical 
resection performed at Chiba University Hospital. All patients provided informed consent 
before any procedures were performed according to a protocol that was reviewed and 
approved by the institutional review board of Chiba University. The resected tissue was 
divided into two portions: one was frozen and stored at -80°C for DNA and RNA 
extraction, and the other was fixed in 10% formalin for pathologic diagnosis. 
Histopathologic diagnosis was performed according to the International Histological 
Classification of Tumors by the Department of Pathology, Chiba University. The tumor 
samples were checked to ensure the presence of tumor in greater than 80% of the resected 
tissue. 
 
Cell culture  
 Nine OSCC-derived cell lines were cultured in Dulbecco’s modified Eagle 
medium F-12 (Sigma, St. Louis, MO) supplied with 10% heat-inactivated fetal bovine 
serum (Sigma), and 1% antibiotic-antimycotic solution (Sigma). Cells were stored at 
37°C in a humidified atmosphere with 5% CO2. Of them, SCC-4, HSC-2, HSC-3, HSC-4, 
Ca9-22, Ho-1-u-1, and Ho-1-N-1 were obtained from Human Science Research 
Resources Bank (Tokyo, Japan) and SAS and OK-92 were established in our department 
(11).  
  
Genomic DNA and RNA extraction 
 Extraction of genomic DNA was performed using a proteinase K (Takara, Shiga, 
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Japan) digestion and phenol-chloroform extraction procedure. Total RNA was extracted 
using the TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. 
 
RT-PCR analysis 
 cDNAs were generated from 1 µg of total RNAs from OSCC-derived cell lines, 
tumor specimens, and normal mucosa specimens using Ready-To-Go You-Prime 
First-Strand Beads (Amersham Biosciences, Buckinghamshire, UK), and oligodT12-18 
primers according to the manufacturer’s instructions. RT-PCR was performed in a 20 
µl-reaction volume containing 1X EX-PCR buffer (Takara), 2 µM of each primer, 200 µM 
of each dNTP, 50 ng of template cDNA, and 0.01 U of TaKaRa Ex-Taq (Takara) DNA 
polymerase. The primer sequences for the genes of interest were as follows:  C1orf10: 
5’-GCACCAGCACCCAGACACAGGAGT-3’, ’-AGTCTCGGTGTGTGACCCTGCC
TG-3’; GAPDH: 5’-CATCTCTGCCCCCTCTGCTGA-3’, 5’-GGATGACCT 
TGCCCACAGCCT-3’; Cyclin D1: 5’-GCCATGAACTACCTGGACCG-3’, 5’-TGAT 
CTGTTTGTTCTCCTCCGC-3’; p16: 5’-TTATTAGAGGGTGGGGCCGGATCGC-3’, 
5’-GACCCCGAACCGCGACCGTAA-3’; p21: 5’-GCGATGGAACTTCGACTT 
TGT-3’, 5’-GGGCTTCCTCTTGGAGAAGAT-3’; p27: 5’-TGGAGAAGCA 
CTGCAGAGAC-3’, 5’-GCGTGTCCTCAGAGTTAGCC-3’. The amplification was 
performed with one denaturing cycle of 3 min at 95°C, then 30 to 32 cycles of 95°C for 20 
sec, 56°C-68°C for 1 min, and one final extension of 7 min at 72°C. Ten microliters of 
PCR product were electrophoresed on a 3% agarose gel and visualized by staining with 
ethidium bromide. Densitrometric analysis was performed with NIH Image software 
(Image version 1.62; Dr. Rasband, National Institutes of Health, Bethesda, MD). 
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 Quantitative Real-Time PCR (LightCycler) 
 Real-time PCR was carried out to assess the relative gene expression and to 
validate the RT-PCR data. All PCR reactions were performed using the real-time 
fluorescence detection method using the LightCycler System (Roche Diagnostics, 
Mannheim, Germany) with a FirstStart DNA Master SYBR Green I kit (Roche Molecular 
Biochemicals, Indianapolis, IN). A reaction mixture containing the following 
components at the indicated end-concentration was prepared according to the 
manufacturer’s instructions: 9.4 µl water, 1.6 µl MgCl2 (2.5 mM), 1 µl of forward primer 
(20 pmol), 1 µl of reverse primer (20 pmol), and 2µl FastStart DNA Master SYBR Green 
I mix. Fifteen microliters of the reaction mixture was distributed into precooled 
capillaries and 20 ng of reverse-transcribed total RNA in a volume of 5 µl was added as 
PCR template. The same primers as described in RT-PCR were used to verify the 
expression of the selected genes. The GAPDH was chosen for normalization of the data. 
To prepare the standard curve 1 µg of RNA from oral normal tissue and keratinocyte cells 
were reverse-transcribed and dilutions of 200, 20, 2, 0.2 ng of cDNA were made. PCR 
cycle conditions were the following: initial denaturation was for 10 min at 95°C and 
followed by 45 cycles of amplification at 95°C (10 sec) for denaturation, 56-68°C (10 
sec) for annealing, and 72°C for extension, with a temperature slope of 20°C/sec. After 
amplification, the temperature was slowly elevated above the melting temperature of the 
PCR product to measure the fluorescence and thereby to determine the melting curve. A 
negative control without cDNA template was performed to assess the overall specificity. 
A relative value for the initial target concentration in each reaction was determined on the 
basis of the kinetic approach using the LightCycler software, version 3.5. 
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Plasmid construction 
To obtain C1orf10 transfectants, we used an ecdysone-inducible expression kit 
(Invitrogen) as recommended by the manufacturer. A pME-18SFL3 vector, which 
contained the full-length C1orf10 cDNA obtained from the previously built OSCC 
cDNA library (3), was used as a template to construct the ecdysone-inducible C1orf10 
expression vector. To construct an expression vector in-frame with a C-terminal 
polyhistidine tag and V5 epitope the stop codon of C1orf10 gene was modified by 
site-directed mutagenesis. The 5'-terminal side fragment was excised from 
BamHI/EcoNI sites. The 3'-terminal side fragment was PCR-amplified to change the stop 
codon into a NotI recognition site using the following PCR primers: 
5'-CAGGCAGTGGTCAAAGATGG-3' and 
5'-ATTGGAGTCGGGGCGGCCGCGGCTTGGTGC-3' (the underline indicates the 
region of the mutation). After PCR amplification, the fragment was digested with EcoNI 
and NotI. The two fragments then were ligated into the BamHI/NotI sites of 
pIND/V5-HisA vector (Invitrogen) with Ligation High (Toyobo, Japan). The sequence 
direction of the constructed C1orf10 expression vector (pIND-c1) was confirmed by 
DNA sequencing. 
 
Transfection 
 Transfection was accomplished using the FuGENE 6 Transfection Reagent from 
Roche Molecular Biochemicals (Indianapolis, IN). To assay the transfection and its 
efficiency, SAS cells were co-transfected with pVgRxR and pIND/V5-His/lacZ. 
Transfection efficiency was estimated by measuring the β-galactosidase activity of cells 
after treatment with 5, 10, and 20 µM of ponasterone A for 24 h. Transfected cells induced 
with 20 µM ponasterone A had 2-fold greater β-galactosidase activity than the uninduced 
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one. The same procedure was done with other OSCC cell lines and cells that 
demonstrated the greater β-galactosidase activity (HSC-3-c1, and HSC-4-c1) were 
chosen for transient transfection. 
 
Establishment of Stable Cell transfectant and transient transfection 
The stably C1orf10 transfected SAS-c1 cell line was generated by 
co-transfecting pVgRxR and pIND-c1 into the OSCC-derived cell line SAS. Twenty-four 
hours following transfection, 400 µg/ml of G418 (Sigma) and 200 µg/ml Zeocin 
(Invitrogen) was added to the culture for select positive clones.  To identify clones that 
contained the inducible C1orf10, cells were treated with 5, 10, and 20 µM of ponasterone 
A for 24 h. After ponasterone A treatment, cells were harvested, total RNA was extracted, 
and the expression of C1orf10 gene was analyzed by RT-PCR as described above. 
 For transient transfection HSC-3 and HSC-4 cells were co-transfected with 
pVgRxR and pIND-c1. Twenty-four hours after transfection, HSC-3-c1 and HSC-4-c1 
cells were treated with 5, 10, and 20 µM of ponasterone A and cultured for more 96 h for 
further studies. The expression of C1orf10 was assessed by RT-PCR analysis.  
 
Western blot analysis 
 Cells cultured in dishes 10 cm in diameter were washed with phosphate buffered 
saline (PBS), harvested, and treated with lysis buffer containing 10 mM Tris base (pH 
8.0), 400 mM NaCl, 3 mM MgCl2, 0.5% NP-40, 100 mM phenylmethylsulfonyl fluoride, 
and 0.01% protease inhibitor cocktail (Sigma) at 4°C for 30 min. Cell lysates were 
centrifuged at 15 000 rpm for 30 min at 4°C and the supernatant was used for the 
subsequent analyses. Protein concentrations were determined using the Bio-Rad protein 
assay (Bio-Rad Laboratories, Hercules, CA). Fifty micrograms of total protein were 
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protein denatured in SDS sample buffer (60 mM Tris-HCl [pH 6.8], 10% glycerol, 2% 
SDS, 0.005% bromophenol blue, and 5% β-mercaptoethanol) and loaded onto 12% 
SDS-polyacrylamide gels. The gels were transferred onto immunoblot PVDF membranes 
(Bio-Rad). Equal loading of protein was confirmed by staining the membrane with 
Ponceau S (Sigma). After blocking with 5% nonfat skim milk and 0.05% Tween 20 in 
Tris-buffered saline (TBS) for 1 h, blots were incubated with 1:1000 dilution of anti-His 
(C-term)-HRP antibody (Invitrogen) or anti-V5-HRP antibody (Invitrogen) for 2 h. After 
several washings, blots were developed using ECL Western blotting detection reagents 
(Amersham). 
 
Cell growth assay and MTT assay 
 Transfected cells SAS-c1, HSC-3-c1, and HSC-4-c1 were plated in 24-well 
plates. The cells were treated with 20 µM ponasterone A and cultured for 72 h. To 
eliminate the effect of the ethanol used to dissolve ponasterone A, we also performed 
experiments with addition of ethanol. The cells were washed with PBS, dissociated with 
0.025% trypsin-EDTA (Sigma), and cells were counted with a hemocytometer. 
 SAS-c1, HSC-3-c1 and HSC-4-c1 cells were plated at 1 × 103 of cell density in 
96-well plates and cultured with (5, 20 µM) or without ponasterone A.  Cells were 
harvested for MTT assay at 24, 48, 72, and 96 h after ponasterone A treatment. MTT 
[3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (Dojindo, Kumamoto, 
Japan) was added to the cultures (500 µg/ml), incubated at 37°C for 4 h, the intracellular 
formazan crystals were solubilized with isopropanol containing 0.01 N HCl, and the 
absorbance of the solution at 570 nm was measured using a microplate reader (Model 550, 
Bio-Rad Laboratories). 
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BrdU incorporation 
 To determine the proportion of cells in S-phase, SAS-c1, HSC-3-c1 and 
HSC-4-c1 cells were seeded in 96-well plates at 1 × 103 cells per well and treated for 24, 
48, 72 and 96 h with 0, 5, 20 µM of ponasterone A. Eighteen hours before the ending of 
the treatment, 20 µM BrdU was added to the culture medium. Cells were fixed in 4% 
paraformaldehyde for 10 min, permeabilized with 0.2% Triton X-100 for 5 min, 
denatured at room temperature for 1 h in 2N HCl, and neutralized with 0.1 M sodium 
tetraborate. The incorporated BrdU was detected by immunofluorescence method. 
Briefly, the cells were blocked with 3% BSA for 30 min, incubated with anti-BrdU mouse 
monoclonal antibody (1:100)(Sigma) for 1 h and subsequently with FITC-conjugated 
anti-mouse IgG secondary antibody (1:500) (Sigma). The cells were then analyzed on a 
fluorescence microscope and the number of BrdU-positive nuclei was expressed as a 
percentage of the total cells visualized. Cells were counted in at least 5 random fields in 
each sample and the experiments were performed in triplicate. 
 
Cell cycle analysis 
 DNA content was measured following staining of cells with propidium iodide 
(PI). SAS-c1 cells were treated with 0, 5, and 20µM of Ponasterone A for 48 h. Cells were 
subsequently trypsinized, washed twice in cold PBS, fixed in 70% and stored at 4°C. 
After fixation cells were pelleted, washed twice with 1% FBS/PBS and incubated for 30 
min at 37°C in 1mg/ml RNAse A(Sigma) to eliminate double-strand RNA. For staining 
the DNA content, cells were incubated with 50 µg/ml PI (Sigma) for 10 min in the dark. 
Flow cytometric determination of DNA content was analyzed by a FACScalibur 
(Becton-Dickinson, San Jose, CA) flow cytometer. For each sample, 20 000 events were 
stored. The fractions of the cells in G0-G1, S, and G2-M phases were analyzed using 
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CELLQuest software (Becton-Dickinson). 
 
In situ cell apoptosis detection assay 
 SAS-c1, HSC-3-c1, HSC-4-c1 and respective mock transfectants were plated in 
96-well dishes at a density of 1×103 cells per well. Cells treated with 0, 5, 20 µM 
ponasterone A for 48 h were analyzed for apoptosis by terminal deoxynuleotidyl 
transferase (TdT) mediated dUTP nick end labeling (TUNEL) procedure, using an in situ 
apoptosis detection kit (Takara). In brief, cells were fixed in 4% paraformaldehyde for 10 
min and endogenous peroxidase was blocked with 0.3% H2O2. After treatment with 
Permeabilisation Buffer (Takara) for 1 h, cells were incubated with TdT Enzymes plus 
Labeling Safe Buffer (Takara) at 37°C for 1 h. In this reaction residues of FITC-labeled 
dUTP are added to the 3’-OH end of the fragmented DNA. The cells were then incubated 
with peroxidase-conjugated anti-FITC antibody to detect the FITC-labeled DNA, and 
visualized with 3,3’-diaminobenzidine (DAB) solution (Dako, Kyoto, Japan). Cells were 
observed on a phase-contrast microscope and apoptotic cells were counted and expressed 
as a percentage of total cells. Experiments were performed in triplicate. 
 
Mutation analysis 
 To screen the sequence variations of the C1orf10 gene, we performed direct 
sequencing of its entire coding region, which is comprised of three exons. Seven sets of 
oligonucleotide primers were used to amplify the entire coding region of the C1orf10 
gene. Primer sets for PCR amplification are shown in Table 1. The genomic DNA used for 
sequencing was obtained from four OSCC-derived cell lines and three blood samples. 
Direct sequencing was performed as follows: after PCR amplification, products were 
purified with Wizard PCR Preps DNA Purification System (Promega, Madison, WI) 
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according to the instructions of the manufacturer. Sequencing was performed in an ABI 
3700 DNA sequencer (Applied Biosystems, Foster City, CA) using the BigDye 
terminator sequencing kit (Applied Biosystems). Sequences were compared with the 
GenBank accession no. AF185276 sequence of the human C1orf10 gene.  
 
5-aza-2’-deoxycytidine treatment 
 To assess reactivation of the gene expression, the cells were treated with 2 µM of 
the DNA methyltransferase inhibitor, 5-aza-2’-deoxycytidine (Sigma), as described 
previously (12).  On day 5, the cells were washed with PBS and grown for an additional 
10 days without the demethylating chemical, after which cells were harvested, total RNA 
was extracted, and the expression of the C1orf10 gene was evaluated by RT-PCR as 
described above.  To use as a control of demethylation we performed RT-PCR to detect 
the expression of p16 gene, a gene known to be hipermethylated in OSCC (10). The 
primers for p16 gene were the following: forward primer, 5’-TTATTAGAGG 
GTGGGGCCGGATCGC-3’; reverse primer, 5’-GACCCCGAACCGCGACCGTAA-3’.  
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Table 1   Primers used to C1orf10 gene mutation search 
Primer Sequence 
Exon-fragment 
Forward primer (5’-3’) Reverse Primer (5’-3’) 
exon 1 ATCCTGTCTAAAACAAGAGCC GTTTTATGAGCTCAGATCACC 
exon 2 AAGACCTAGCAGCAGACGTGC GGTTTCACTCTCCTGCTATGT 
exon 3-1 AAGCTGGCAGCAGATTGGAA TCTGGAACCCTGCTGGCTCT 
exon 3-2 TGGGCGAAGGACAGAGAAGT TTCTTCCTGTCTGGTGGCTG 
exon 3-3 AGAGAGACAGCCACAGACCA TGCCTGTATCTGAGTGTGTC 
exon 3-4 GAGATCCACGGTCAAGGCAG GTCATCAACCCATTCCTCAC 
exon 3-5 GAGTCAGGAAGGCAGGAGTG AGGACAAGCCAAACTCTCTC 
Seven sets of primers were used to screen the 3 exons of C1 orf10 gene 
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RESULTS 
Down-regulation of C1orf10 in OSCC 
 cDNA microarray experiments revealed the down-regulation of C1orf10 in 
OSCC (3). To confirm this, I assessed the level of C1orf10 mRNA expression in primary 
tumors and OSCC-derived cell lines by RT-PCR and compared the results with the 
expression of the housekeeping gene GAPDH. From the 40 pairs of OSCC and its 
adjacent normal tissue assessed, I found a decrease in C1orf10 expression in 24 cases 
(60%). Representative cases of RT-PCR are shown in Fig 1A. To validate the RT-PCR 
analysis, 10 cases that showed C1orf10 down-regulation were also examined with 
quantitative Real-Time PCR (Fig 1B). Expression of C1orf10 was detected in primary 
cultured oral keratinocyte and undetectable in the nine OSCC-derived cell lines examined 
(Fig 1C). 
 
Expression of exogenous C1orf10 in OSCC cell line 
To investigate the function of C1orf10 in OSCC, I established a stable C1orf10 
transfectant in the OSCC-derived cell line SAS, controlled by an ecdysone-based 
inducible system. The stable transfected SAS clone (SAS-c1) was treated with 
ponasterone A, and the expression of C1orf10 was detected by RT-PCR and Western blot 
analysis. The expression of C1orf10 was inducible in a dose-dependent manner (Fig 2A, 
2B). The C1orf10 protein fused with a C-terminal polyhistidine tag and V5 epitope was 
detected with monoclonal anti-His and anti-V5 antibodies by Western blot (Fig 2B, 2C). 
The expressed protein was detected at a doubled molecular size (100 kDa) than the 
predicted one (50 kDa). C1orf10 protein has homology with S100 family proteins and 
bacterial ice nucleation protein (1). These two proteins are known to form dimmers (13 
-16). Moreover, S100 proteins can form dimmers even under reducing and denaturing 
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conditions (17,18), suggesting that C1orf10 could form dimmers, and explains the 
doubled size of the expressed protein.    
To further study the effects of C1orf10 expression in OSCC, another 2 
OSCC-derived cell lines (HSC-3, and HSC-4) were transiently transfected with pVgRxR 
and pIND/c1orf10. The expression of C1orf10 in the transfectants HSC-3-c1 and 
HSC-4-c1 was inducible with ponasterone A (Fig 2A), and used for the subsequent 
analysis.   
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Fig. 1. Expression of C1orf10 in OSCC specimens and OSCC-derived cell lines. 
Expression of C1orf10 in OSCC specimens and OSCC-derived cell lines. (A) Representative 
results of RT-PCR indicating C1orf10 mRNA levels of tumor tissues (T) from five patients 
compared with those from adjacent normal tissue (N). There is a significant reduction of C1orf10 
gene expression in tumor tissues. M, molecular marker. (B) Quantification of mRNA levels of 
tumor tissues (T) and adjacent normal tissue (N) from 10 cases by real-time PCR. Significant 
down-regulation of the C1orf10 gene was seen in tumor tissues. (C) Expression of C1orf10 in 
nine OSCC-derived cell lines. Primary cultured human oral keratinocyte was used as positive 
control.  Expression of C1orf10 was undetectable in OSCC-derived cell  l ines.  
M, molecular marker.
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Fig. 2.  Expression of C1orf10 in transfected OSCC cells.(A) RT-PCR analysis of 
C1orf10 expression on OSCC-derived cell lines co-transfected with pVgRxR and 
pIND/c1orf10 (SAS-c1, HSC-3-c1, and HSC-4-c1) treated with ponasterone A. The 
concentrations  (µM)  of  ponasterone  A  used  are  indicated  above the panel.  Positive 
control (PC) is a primary cultured human oral keratinocyte. GAPDH was used as an 
internal control.  (B) Western blot analysis with anti-His antibody of the SAS-c1 cells 
after induction by ponasterone A.  The concentration (µM) of ponasterone A used for 
induction is indicated above the blot.  Ponasterone A dose-dependent expression of 
C1orf10 protein is observed at 100 kDa.   (C) Western blot analysis with anti-V5 antibody 
of SAS-c1 treated with 20µM ponasterone A.  To further study the effects of C1orf10 
expression in OSCC, another 2 OSCC-derived cell lines (HSC-3, and HSC-4) were 
transiently transfected with pVgRxR and pIND/c1orf10. The expression of C1orf10 in 
the transfectants HSC-3-c1 and HSC-4-c1 was inducible with ponasterone A (A), and 
used for the subsequent analysis. 
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  C1orf10 expression inhibits cell proliferation in OSCC cell lines 
 In order to analyze the biological function of C1orf10 in OSCC, I first examined 
the effects of exogenous expression of C1orf10 on cell growth. SAS-c1, HSC-3-c1, and 
HSC-4-c1 cells had a significant decrease in cell numbers (47 %, 26 %, and 47.2 %, 
respectively) after 72 h of ponasterone A treatment compared with untreated cells (Fig 3). 
Control experiments with addition of ethanol did not showed differences in cell numbers 
(data not shown). To analyze the growth rate, we performed MTT assay of C1orf10 
transfected cells in induced and uninduced conditions over 96 h. Significantly decreased 
rate of proliferation was observed in all 3 transfectants. In SAS-c1 cells the decrease in 
cell growth was directly proportional to C1orf10 induction. The cell proliferation of 
SAS-c1 cells treated 96 h with 5 µM and 20 µM ponasterone A decreased by 27% and 
40%, respectively (Fig 4A). HSC-4-c1 cells had a significant decrease in growth rate after 
72 h of treatment (Fig 4B).  The cell growth in HSC-3-c1 decreased by 50.7 % when 
treated with 20 µM ponasterone A, and a slightly decline was observed with 5 µM 
ponasterone A (Fig 4C). Cells transfected with an empty vector showed no significant 
difference in the growth rate after ponasterone A treatment (data not shown). These 
results indicate that the expression of C1orf10 in OSCC cell lines negatively regulates the 
cell growth.  
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Fig. 3.  Effects of C1orf10 overexpression in cell numbers.  
The effects of exogenous C1orf10 expression in total cell numbers of transfected cells 
treated with (20µM) or without ponasterone A for 72 h. A significant decline in total cell 
numbers are observed on cells treated with ponasterone A. Data are presented as means 
±SD from three independent experiments. Student’s t test was used to analyze differences 
between cells treated or untreated with ponasterone A: *, p<0.05, **, p<0.0005.  
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Fig. 4. The effects of C1orf10 overexpression in cell growth of transfected OSCC 
cells.   SAS-c1, HSC-3-c1,  and  HSC-4-c1  cells were cultured with (5, 20 ?M) or 
without ponasterone A and cells were harvested for MTT assay after 24, 48, 72, 96 h. (A) 
The cell proliferation rate decreased in SAS-c1 cells in ponasterone A dose-dependent 
manner. (B) HSC-3-c1 showed visible reduction in cell proliferation while induced with 
20 ?M ponasterone A, and a slightly decrease with 5 ?M ponasterone A.  (C) HSC-4-c1 
induced with ponasterone A showed a significant reduction in the growth rate. Results 
represent the means ?SD of six independent experiments.  Statistical analysis was 
carried out with the Student’s t test. *, p<0.01, **, p<0.05.  
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Correlation of C1orf10 expression and apoptosis in OSCC cells 
 To examine whether the reduction in cell growth of cells expressing C1orf10 is 
due to apoptosis, I analyzed the DNA fragmentation by TUNEL assay.  As shown in Fig 
5A, an increase in TUNEL positive cells was detectable in C1orf10-induced cells by 
ponasterone A. However, the total percentage of cells that underwent to apoptosis (9.2 % 
in SAS-c1 cells) was small in comparison with the percentage of growth inhibition (Fig 
5B), indicating that apoptosis is not the main cause for the decrease in cell numbers in 
C1orf10-expressing cells. 
 
Expression of C1orf10 reduces S-phase cells 
 To confirm the effect of C1orf10 expression in OSCC cells proliferation, I 
assessed the rate of cell cycle, by measuring BrdU incorporation. Because BrdU is 
incorporated instead of thymidine into the DNA during DNA synthesis in proliferating 
cells, the number of cells that incorporate BrdU reflects the percentage of total S-phase 
cells. C1orf10-transfected cell lines (SAS-c1, HSC-3-c1, HSC-4-c1) were treated with 
ponasterone A and after addition of BrdU into the culture, cells were harvested at 24, 48, 
72, and 96 h. Positive staining was detected by immunofluorescence and expressed as a 
percentage of the total visualized cells (Fig 6A). The percentage of S-phase cells in the 
SAS-c1 cells treated with ponasterone A decreased by 20.4% compared with the 
untreated cells, and the reduction in BrdU incorporating cells was inversely proportional 
to the increase in C1orf10 expression (Fig 6B). Similar results were obtained with the 
transient C1orf10-transfected HSC-3-c1 and HSC-4-c1 cells (data not shown). The 
difference in S-phase cells numbers in the cells transfected with an empty vector was not 
significant. The expression of C1orf10 substantially decreased the fraction of cells in the 
S-phase of the cell cycle, indicating that C1orf10 can arrest the cell growth. These results 
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demonstrated that the overexpression of C1orf10 in OSCC-derived cell lines inhibits the 
cell proliferation by interfering in the cell cycle progression. 
 
Cell cycle progression is inhibited by C1orf10 expression. 
 To address more specifically the mechanism by which C1orf10 inhibits the cell 
cycle progression, we performed FACS analyses of SAS-c1 cells treated or not with 
ponasterone A for 48 h. The overexpression of C1orf10 induced an increase in the 
percentage of cells in the G1 phase of the cell cycle? (from 76.7 to 86 %), parallel to a 
decrease in the percentage of cells in the S-phase (from 8.39 to 4.6 %) (Fig 7A and 7B).  
These results indicate that C1orf10 can inhibit OSCC cell proliferation by the induction 
of G1 arrest. 
To identify the mechanism by which C1orf10 blocks the G1/S progression, we 
assessed the expression level of Cyclin D1 and cyclin-dependent kinase inhibitors in 
SAS-c1 cells treated or not treated with ponasterone A. We detected a reduction in the 
expression of Cyclin D1 mRNA after C1orf10 expression (Fig 7C).  However, we could 
not detect the expression of none of the cyclin-dependent kinase inhibitors assessed (p16, 
p21, and p27) (Fig 7C). These results indicate that the arrest of the cell cycle progression 
from G1 to S-phase by C1orf10 expression is due to the down-regulation of Cyclin D1, 
instead of the negative regulation from cyclin-dependent kinase inhibitors. 
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Fig. 5.   Effects of C1orf10 overexpression on apoptosis in OSCC cell lines.     
(A) DNA fragmentation of apoptotic cells was detected by TUNEL assay.  Left panel:  
SAS-c1 cells without ponasterone  A  treatment.  No apoptotic cells were detected.  Right 
panel:  SAS-c1 treated  with  20 ?M ponasterone A for 72 h.  Some apoptotic cells were 
detected. Arrows demonstrated some apoptotic cells.  (B) Percentage of apoptotic cells in 
OSCC-derived cells SAS, HSC-3, and HSC-4 transfected with C1orf10 or empty vector 
(mock) and treated with 20 ?M ponasterone A. A small percentage of cells 
overexpressing C1orf10 underwent apoptosis. Untreated C1orf10-transfected cells were 
used as control (Control). Data represent the means ? SD of three independent 
experiments. 
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Fig. 6.   BrDU incorporation assay    
BrdU incorporation of C1orf10 stable transfectant SAS-c1 cells after ponasterone A 
treatment.   SAS-c1 cells treated with 20 ?M   ponasterone  A  (Pon A +) or  without  
treatment (Pon A -) were stained with anti-BrdU   antibody,   followed  by  FITC  labeled  
anti-mouse  IgG.    Positive proliferating cells showed   nuclear   immunofluorescence    
(right panels).   Left   panels   are phase-contrast micrographs visualizing the total cells. 
Bar = 20 ?m. (D) Percentage of total S-phase cells of SAS-c1  cells  treated with 0, 5, 20 
?M ponasterone A. Cells expressing C1orf10 show decrease in S-phase cells percentage.  
Nonstimulated  transfected cells and parental SAS cells  served  as controls.  Results  
represent  the  means  ?SD  of examination of 5 fields in 3 independent  experiments. 
Statistical analysis was carried out with the Student’s t test. *, p<0.05, **, p<0.01, 
compared with nonstimulated cells. 
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Fig. 7. The effect of induced C1orf10 expression on the cell cycle.  
SAS-c1 cells were treated with 0, 5, 20 µM of ponasterone A for 48 h, fixed and stained 
with propidium iodide, and then analyzed by FACScalibur. (A) Flow cytometry analysis 
of the DNA content of SAS-c1 not treated (left panel) and treated with 20µM ponasterone 
A (right panel). (B) Percentage of G1 phase cells and S-phase cells in SAS-c1 cells after 
ponasterone A treatment. Induction of C1orf10 expression increased the percentage of G1 
phase cells (from 76.7 to 87%) parallel to a decrease in S-phase cells (from 8.39 to 4.6%), 
indicating cell cycle arrest at G1/S transition. (C) RT-PCR analysis of Cyclin D1, p16, p21, 
and p27 expressions in SAS-c1 cells induced or not with ponasterone A (left panels). 
Quantification of Cyclin D1 mRNA levels by real-time PCR (right panel).  Cyclin D1 
expression was down-regulated and cyclin-dependent kinase inhibitors expression was 
not detected after C1orf10 induction. 
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Search for the mechanism of C1orf10 gene down-regulation 
 To cast light on the molecular mechanisms underlying the down-regulation of 
C1orf10 gene in OSCC, I first searched for structural abnormalities on chromosome and 
gene. Loss of heterozigosity (LOH) is frequently related in several microsatellite loci on 
OSCC (19-27). LOH on three microsatellite regions, localized in chromosome 1q 
(D1S484, D1S2346, and D1S2347), did not detect structural alterations (data not shown). 
To search for sequence variations of C1orf10 gene, I performed direct sequence analysis 
of the entire coding region of C1orf10 in four OSCC-derived cell lines. I did not detect 
any mutation at the C1orf10 gene in the OSCC cell lines.  
 I then considered the possibility that promoter methylation could be involved in 
C1orf10 down-regulation. To search for abnormal methylation status of the C1orf10 gene, 
I treated cells that lost C1orf10 expression with the demethylating agent 
5-aza-2’-deoxycytidine (5-Aza-CdR). The restoration of p16 expression, a gene known to 
be hypermethylated in OSCC (10), was used as a control for demethylation. C1orf10 was 
not restored (Fig 8), indicating that the loss of expression was not due to 
hypermethylation.  
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Fig. 8. RT-PCR analysis of OSCC-derived cells treated with the demethylating 
agent 5-aza- 2’-deoxycytidine (5-aza-CdR).  
OSCC-derived cells were treated with 2 ?M of 5-aza-CdR,  and  reexpression of 
C1orf10 (upper panel) was analyzed by RT-PCR. RT-PCR for p16 was used as positive 
control for demethylation. RT-PCR for GAPDH was used as internal control.  The 
reactivation of p16 was observed in 7 of 9 OSCC cell lines, instead C1orf10 reexpression  
was not observed. 
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DISCUSSION 
 C1orf10 was initially identified by differential display as a gene highly 
expressed in esophageal mucosa and down-regulated in esophageal carcinoma tissues 
and cell lines (1). C1orf10 has been proposed as a squamous-cell specific gene, because 
of its expression in esophageal tissue, cervical squamous epithelium, and murine skin, 
and absence of expression in another 15 glandular tissues (1, 2, 4). By an in-house cDNA 
microarray specific for oral cancer, I found that C1orf10 gene expression was strongly 
down-regulated in OSCC (3). These findings lead to the hypothesis that C1orf10 might be 
a tumor suppressor gene associated with squamous cell carcinoma and prompted us to 
study the expression patterns and the roles of C1orf10 in OSCC. 
In the present study, I examined the expression of C1orf10 in OSCC tissues and 
OSCC cell lines by RT-PCR. Expression of C1orf10 was observed in normal oral mucosa 
and primary cultured keratinocytes, while this gene expression was down-regulated in 
OSCC tissues, and absent in OSCC cell lines. These results were consistent to those 
previous findings. To determine whether the down-regulation of C1orf10 expression had 
relevance to OSCC carcinogenesis, C1orf10 was overexpressed in three OSCC cell lines. 
Morphological changes of OSCC-derived cells were not observed after induction of 
C1orf10 expression. I observed that the overexpression of C1orf10 caused a significantly 
decreased rate of proliferation. Moreover, cells overexpressing C1orf10 showed a decline 
in S-phase cells by BrdU incorporation assay, an arrest in G1 phase of cell cycle, and did 
not induced significant cell apoptosis. These observations suggested that the inhibitory 
function of C1orf10 in regulating cell proliferation was likely due to a block in the cell 
cycle. 
Clorf10 protein is characterized by the presence of an S100 EF-hand 
calcium-binding motif at its N-terminal (1). S100 proteins are known to play roles in cell 
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proliferation. S100A11 is down-regulated in immortalized human fibroblasts and 
cancerous tissues (28, 29). S100B and S1002 are classified as growth suppressor in 
tumors (30, 31). S100B functions in negative cell proliferation by an arrest in the cell 
cycle at G1 phase. In this study, the overexpression of the C1orf10 gene inhibited cell 
proliferation in OSCC cells by arresting the cell cycle at G1/S transition. Moreover, I 
detected the down-regulation Cyclin D1 and lack of expression of any cyclin-dependent 
kinase inhibitors. These results suggest that C1orf10 might arrest the cell cycle at G1 by 
regulating the expression of Cyclin D1.   
 To elucidate the mechanisms of C1orf10 regulation in OSCC, I first searched for 
structural alterations of the gene. Direct sequencing and microsatellite analysis did not 
detect structural alterations. I then considered the possibility of hypermethylation at the 
promoter region as another mechanism involved in the loss of gene function (32). 
Because little is known about the promoter of the C1orf10 gene, I searched for the 
promoter region with a mammalian promoter prediction program (Promoter 2.0 
Prediction Server, http://www.cbs.dtu.dk/services/promoter); however, no potential PolII 
promoter region was recognized 5 kb upstream of the gene. Thus, I could not perform 
methylation-specific PCR of the promoter region. To search for hypermethylation of the 
C1orf10 gene, cells were treated with the demethylating agent 5-aza-CdR. However, I 
could not detect the restoration of this gene, indicating that the methylation is not the 
mechanism for C1orf10 inactivation.  
The C1orf10 gene is located on chromosome 1q21, where 13 S100 family gene 
members are tightly clustered (33, 34). S100 genes play different roles in cancer 
development (17). For example, S100A4, S100A6, S100A7, and S100B seem to have roles 
such as oncogenes (35, 36), whereas S100B, S100A2 and S100A11 are thought to be 
tumor suppressor genes (29-31). The 1q21 chromosome region is frequently rearranged 
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in tumors, possibly exerting direct or indirect influences on the expression of S100 genes 
in cancer. Furthermore, transcription factors such as p53 activate the promoter region of 
S100A2 (37). The complexity of the regulatory mechanisms of S100 genes in this region 
may be associated with the difficulty of understanding C1orf10 expression.  
In conclusion, the expression of C1orf10 gene was frequently down-regulated in 
OSCC, and its overexpression inhibited the cell proliferation of OSCC-derived cells by 
an arrest of cell cycle progression at G1/S, suggesting that C1orf10 may play an important 
role in OSCC progression.   
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EXPRESSION AND PURIFICATION OF S100A13 
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SUMMARY 
S100 family proteins are small acidic calcium-binding proteins of the EF-hand 
type implicated in intracellular and extracellular regulatory activities. S100 proteins 
are characterized with two EF-hands, one canonical EF-hand at C-terminal and an 
EF-hand specific for S100 proteins. The two EF-hands display different affinities for 
calcium. Within the cells, most of S100 members exist in the form of homo- or 
heterodimers. S100A13 is one of the latest members of the S100 family with some 
distinguished characteristics from other S100 proteins. S100A13 is the unique member 
of S100 family that has ubiquitous expression in a broad range of tissues. Moreover, 
S100A13 does not show conformational changes after calcium binding, which is 
thought to be essential for interaction of S100 proteins with target proteins. To study 
the biochemical and structural characteristics, I expressed and purified human 
S100A13. The cDNA sequence of the coding region of human S100A13 was cloned 
from a cDNA library from human spleen and subcloned into a plasmid vector that have 
been engineered to add a six histidine tag to the N-terminus. The recombinant 
S100A13 was expressed in E. coli BL21 (DE3). The soluble protein was applied 
through a His-Bind column affinity chromatography, and after the cleavage of the 
polyhistidine tag, S100A13 was purified through an anion exchange chromatography. 
The purified S100A13 was analyzed with SDS-PAGE, and pure S100A13 was 
obtained for further analysis to determine the three-dimensional structure of this 
protein.
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INTRODUCTION 
 S100 proteins are small acidic proteins of the EF-hand type. They are 
characterized with two EF-hands, one canonical EF-hand at the C-terminus and an 
S100-specific EF-hand at the N-terminus. Five oxygen-containing amino acid residues 
and a conserved glycine residue coordinate the calcium binding in EF-hands, which 
causes the bending of the loop. The conformational change that occurs in consequence of 
calcium binding is essential for the regulatory function of EF-hand proteins. 
 The determination of three-dimensional (3D) structure of proteins is a powerful 
approach for understanding the protein function at the molecular level. The EF-hand 
structural motif was first reported from the crystal structure of carp parvalbumin (38, 39). 
A number of crystal structures of S100 family proteins have been reported: bovine S100B 
(40), calbindin D9K (41), human S100A7 (42), S100A10 (43), S100A11 (44), S100A12 
(45), and MRP8 (46). 
S100A13 is one of the recently identified proteins from the S100 family. Human 
S100A13 has a molecular mass of approximately 11 kDa and is composed of 98 amino 
acids (47). Differently from the tissue-specific expression of most S100 proteins, 
S100A13 is widely expressed in various types of tissues (48). S100A13 form 
homodimmers and possesses two high- and two low-affinity sites for calcium (48). 
However, it does not show a calcium-dependent exposure of the hydrophobic patches, 
essential for the interaction of S100 proteins with target proteins. Other distinguishing 
characteristic of this S100 protein is that the second EF-hand contains an unusual lysine 
that might influence the Ca2+ binding properties. Furthermore, the positively charged 
C-terminal containing six lysine and two arginine residues could be involved in specific 
protein interactions. S100A13 is known to be associated with the secretion of 
brain-derived fibroblast growth factor-1 (FGF-1) and p40-synaptotagmin in response to 
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heat shock (49, 50). Moreover, S100A13 is believed to be involved in signaling 
complexes and signal transduction cascades because of its translocation in response of 
increase in the intracellular calcium level by angiotensin II (18). 
  In this study, I attempted to express and purify the recombinant human 
S100A13 for further analysis to investigate the molecular structure of S100A13 that has 
distinguished characteristics from other members of S100 family.  
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MATERIALS AND METHODS 
S100A13 Constructs 
 Human S100A13 was cloned from a first-strand cDNA library from human 
spleen (Origene Technologies). The coding region of S100A13 was amplified by 
polymerase chain reaction using specific oligonucleotides containing a 5’ NdeI site 
(5’-GTCCATATGGCAGAACCACTGA-3’) and a BamHI site 
(5’-CTAGGATCCGAAGAGTGCGGTTCTGC-3’) under the following conditions: 95ºC 
for 1 min, 56ºC for 1 min, 72ºC for 2 min, 35 cycles, followed by 10 min of 72ºC 
extension. The polymerase chain reaction product was then purified and cloned into the 
pGEM-T easy vector (Promega). The plasmids were sequenced by an ALF DNA 
sequencer (Amershan Pharmacia Biotech) to verify the open reading frame. The plasmid 
with the correct S100A13 sequence was then cloned into the BamHI and NdeI sites of 
pET-16b vector (Novagen).  
 
Expression of S100A13 
 The S100A13 pET-16b construct was transformed into the BL-21 (DE3) strain 
for expression of the recombinant protein. The expression of S100A13 was induced by 
the addition of isopropyl-1-thio-β-D-galactopyranoside (IPTG) at a final concentration of 
1mM, and cultured at 37ºC. Four hours after induction, the cells were harvested by 
centrifugation at 5 000 rpm for 10 min at 4ºC. The cells were resuspended in 50 mM 
Tris-HCl (pH 8.0), disrupted by sonication, and centrifuged at 15 000 rpm for 20 min at 
4ºC. The soluble fraction was subjected to affinity chromatography on His-bind resin 
chromatography.  
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Purification of recombinant S100A13 
 Purification of the recombinant S100A13 by His-Bind Resin Chromatography  
(Novagen) was performed according to the manufacturer’s protocol. The S100A13 fusion 
protein was then cleaved by Factor Xa protease (Novagen) at 4ºC for 8 hours.  The 
cleavage reaction was blocked by the addition of 2 mM of the serine protease inhibitor 
Pefabloc SC (AEBSF) (Roche). The cleaved protein was then dialyzed against 25 mM 
Tris-HCl (pH 8.1), passed over an Econo-Pac HighQ (Bio-Rad) anion exchange column 
equilibrated in the same buffer, and eluted with a linear gradient of 0-0.1 M NaCl. 
Fractions of the anion exchange were separated for SDS-polyacrylamide gel 
electrophoresis. 
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RESULTS AND DISCUSSION 
Expression of S100A13 
  The coding region of S100A13 was cloned into pET16b expression vector (Fig 
9). BL21 (DE3) transformed with recombinant pET16b-S100A13 expressed a 
N-terminal polyhistidine fused S100A13 protein. Analysis of total bacterial protein by 
SD-PAGE showed a strong induction of protein expression upon addition of IPTG  
(Fig 10A, lane 3) compared with the cell lysate in lane 2 where no IPTG was added. 
The fused S100A13 was expressed as a protein at approximately 14 kDa. To verify the 
best condition of induction the growth culture was induced with different IPTG 
concentrations (0.1 mM, 0.2 mM, 0.5 mM, 1mM, 2mM) (not shown). The best 
inducing condition was 4-hour induction with 1 mM IPTG.  
 
S100A13 purification 
  The S100A13 fused protein in the soluble fraction of the bacterial lysate after 
ultrasonification was purified over a His-Bind Resin column (Fig 10B, lane 2) and 
digested with Factor Xa protease to remove the histidines repeats (Fig 10B, lane 3). 
The digested protein was dialyzed against 25 mM Tris-HCl and passed over the 
EconoPac HighQ anion exchange chromatography column. S100A13 was eluted from 
the anion exchange column in a linear gradient of 0-100 mM of NaCl. The purified 
S100A13 had a molecular mass of approximately 11 kDa, which correspond to the 
calculated expected mass (Fig 10B, lane 4). However as shown in the anion exchange 
chromatography flow-chart the purified S100A13 was eluted in two different peaks 
(Fig 11A, peaks 1 and 2). The collected fractions analyzed by SDS-PAGE showed no 
differences in the purified protein molecular weight (Fig 11B).  
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In order to study the biochemical and structural properties of human S100A13, I 
cloned, expressed and purified a recombinant S100A13. The purified S100A13 showed 
two different elution patterns in the anion exchange chromatography indicating the 
possible elution of the monomer and a dimerized S100A13, which dissociates into the 
monomer under the conditions of SDS-PAGE. The purified S100A13 will be used for 
further studies to determine the 3D structure of this protein. Structural analysis of 
S100A13 will provide clues to understand the calcium-binding properties and the lack 
of conformational changes upon calcium binding of this distinguished member of S100 
family. 
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Fig. 11. Purification of S100A13 through anion exchange chromatography column. 
(A) Anion exchange chromatography of recombinant S100A13 digested with Factor Xa 
protease was performed with EconoPac HighQ column. Elution was performed with a 
linear gradient of NaCl. Proteins were detected at 280 nm. (B) SDS-PAGE analysis of 
peaks 1 and 2 in A. The lane numbers 1 and 2 correspond to the peak numbers in A. No 
difference in the eletrophoresis pattern was observed between the two fractions. 
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